证券代码：000813 证券简称：德展健康 公告编号：2025-079 德展大健康股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有出现议案被否决的情形； 2、本次股东会没有涉及变更以往股东会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议召开时间为 2025 年 12 月 30 日下午 14:30 时 网络投票时间为 2025 年 12 月 30 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 12 月 30 日 9:15－9:25，9:30－11:30 和 13:00－15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为：2025 年 12 月 30 日 9:15－15:00 期间的任意 时间。 2、会议召开地点：新疆维吾尔自治区乌鲁木齐市水磨沟区昆仑东街 789 号 金融大厦 15 层德展健康会议室。 3、会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 4、会议召集人：董事会 5、现场会 ...

T&P 新疆天阳律师事务所 德展健康 2025 年第三次临时股东会 新疆天阳律师事务所 关于德展大健康股份有限公司 2025 年第三次临时股东会 法律意见书 天阳证股字[2025]第 52 号 新疆天阳律师事务所 二○二五年十二月 1 T&P 新疆天阳律师事务所 德展健康 2025 年第三次临时股东会 新疆天阳律师事务所 关于德展大健康股份有限公司 2025 年第三次临时股东会法律意见书 天阳证股字[2025]第 52 号 致：德展大健康股份有限公司 新疆天阳律师事务所（下称本所）接受德展大健康股份有限公司（下称 公司）的委托，委派本所常娜娜律师、李柯迪律师出席公司 2025 年第三次 临时股东会，根据《中华人民共和国公司法》（下称《公司法》）、《中华 人民共和国证券法》（下称《证券法》）和《德展大健康股份有限公司章程》 （下称《公司章程》），按照律师行业公认的业务标准、道德规范和勤勉尽 责精神，对有关的文件和事实进行核查与验证，并出具法律意见。 本所律师已经对公司提供的与本次股东会有关的文件材料进行了核查验 证。在进行核查验证过程中，公司已向本所保证，其已提供了本所律师认为 的为出具本法律意见书所必需的材料 ...

Group 1 - The core point of the article is that 德展健康 (Dezheng Health) has stated that its currently sold drugs do not include Oseltamivir [1] Group 2 - The company made this announcement on its investor interaction platform [1]

Group 1 - The company announced that its Wuhan Weikang Psychiatric Hospital is set to begin operations in the first half of 2025 [1] - The Hainan Decheng International Health and Wellness Complex project is currently under construction and has not yet commenced operations [1]

Group 1 - The core point of the article is that 德展健康 (Dezhang Health) has announced the operational timeline for its Wuhan Weikang Psychiatric Hospital, which is set to begin operations in the first half of 2025 [1] - The Hainan Decheng International Medical and Health Complex project is currently under construction and has not yet commenced operations [1]

Group 1 - The company announced that Wuhan Weili Kang Mental Health Hospital began operations in the first half of 2025 [2] - The Hainan Decheng International Health and Wellness Complex project is currently under construction and has not yet started operations [2]

Group 1 - The core point of the article is that Dezheng Health (000813.SZ) announced the resignation of its Vice President Wang Shubin due to personal reasons [1] - Wang Shubin will no longer hold any positions within the company or its subsidiaries after the resignation takes effect [1]

Company Governance - The company announced the appointment of Mr. Gao Tao as the Secretary of the Board and Ms. Wu Ling as the Chief Financial Officer, enhancing its governance structure [1] - The appointments were approved by the Board of Directors following nominations from the Chairman and the Co-Chairman [1] Financial Performance - For the first half of 2025, the company's revenue composition is as follows: 99.0% from the pharmaceutical industry, 0.63% from peptides, and 0.37% from other sources [1] - The current market capitalization of the company is 8.1 billion yuan [2]

Group 1 - The company Dezheng Health (SZ 000813) announced the resignation of Mr. Wang Shubin from the position of Deputy General Manager and related roles in subsidiaries due to personal reasons [1] - After the resignation takes effect, Mr. Wang will no longer hold any positions within the company or its subsidiaries [1] - As of the report, Dezheng Health has a market capitalization of 8.1 billion yuan [1] Group 2 - For the first half of 2025, the revenue composition of Dezheng Health is as follows: 99.0% from the pharmaceutical industry, 0.63% from peptides, and 0.37% from other sources [1]

Core Viewpoint - Dezheng Health (000813) announced the appointment of a new auditing firm for its 2025 financial report and internal control audit, following the expiration of its contract with Zhongxing Caiguanghua Accounting Firm [1] Group 1 - The company has decided to select a new auditing firm through a bidding process to meet its business development needs and overall audit requirements [1] - Xinyong Zhonghe Accounting Firm has been chosen as the new auditor for the company's 2025 financial report and internal control audit [1]